<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328029</url>
  </required_header>
  <id_info>
    <org_study_id>2999</org_study_id>
    <nct_id>NCT00328029</nct_id>
  </id_info>
  <brief_title>Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population</brief_title>
  <official_title>Assessment of Respiratory Functions After a Conditioning Regimen With Busulfan for Allograft or Autograft in a Unicenter Pediatric and Prospective Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <brief_summary>
    <textblock>
      Recently, several conditioning regimens did not include total body irradiation (TBI) anymore,
      especially in the case of young children due to cognitive sequelae and late effects on growth
      and height. Thus, such effective chemotherapy conditioning regimens were developed to avoid
      these complications. Busulfan is one of the major drugs used in these treatments, but, is
      also administered in high dose chemotherapy followed by autograft. In both situations, long
      term pulmonary side effects were diagnosed in a few cases. Even if the occurrence is not very
      frequent, the clinical management is a real challenge regarding the reduced quality of life
      and life expectancy of these patients. Up to now, no correlation was done between respiratory
      sequelae and busulfan pharmacokinetics. Hence, in the investigators' pediatric
      onco-hematological unit, a prospective study will begin and last three years to assess the
      respiratory side effects due to busulfan and their potential links with individual drug
      pharmacokinetic measures. These results will be compared to patients treated with TBI during
      the same period of time.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of respiratory side effect frequency in the two years follow up of allograft or autograft treated with busulfan</measure>
    <time_frame>before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison to respiratory side effect frequency with TBI conditioning regimen</measure>
    <time_frame>before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Busulfan pharmacokinetics</measure>
    <time_frame>after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h ; 3 h after 2nd Busulfan taken ; 3 hours after 3rd Busulfan taken ; 3 h after 4st Busulfan taken ;3 h after 5st Busulfan taken ;3 h after 6st Busulfan taken</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Establish a potential link between respiratory side effects and busulfan pharmacokinetics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Signs and Symptoms, Respiratory</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>5mg/kg/day (oral route : 4 doses/day for 4 days)</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>respiratory function tests</intervention_name>
    <description>respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).</description>
    <other_name>before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacokinetics, done during the treatment</intervention_name>
    <description>12 blood collections :
after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.
3 hours after 2nd taken of Busulfan
3 hours after 3rd taken of Busulfan
3 hours after 4th taken of Busulfan
3 hours after 5th taken of Busulfan
3 hours after 6th taken of Busulfan.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients above 3 years old treated by busulfan or TBI in their conditioning regimens
             before allograft or busulfan in high dose chemotherapeutic regimens followed by
             autograft will be included after parents informed assent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Lutz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Service de Pédiatrie Onco-Hématologie - Hôpital de Hautepierre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Lutz, MD</last_name>
    <phone>3.33.88.12.80.90</phone>
    <email>patrick.lutz@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natacha Entz-Werle, MD</last_name>
    <phone>3.33.88.12.80.99</phone>
    <email>natacha.entz-werle@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Explorations Fonctionelles Respiratoires - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charloux Anne, MD</last_name>
      <phone>3.33.88.11.61.22</phone>
      <email>anne.charloux@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Oswald Monique, MD</last_name>
      <phone>3.33.88.11.68.61</phone>
      <email>monique.oswald@chru-strasbourg.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie Onco-Hématologie - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lutz, MD</last_name>
      <phone>3.33.88.12.80.90</phone>
      <email>patrick.lutz@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Natacha Entz-Werle, MD</last_name>
      <phone>3.33.88.12.80.99</phone>
      <email>natacha.entz-werle@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Lutz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natacha Entz-Werle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine COJEAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie BAYART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2006</study_first_submitted>
  <study_first_submitted_qc>May 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2006</study_first_posted>
  <last_update_submitted>February 24, 2009</last_update_submitted>
  <last_update_submitted_qc>February 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christine GEILLER</name_title>
    <organization>Direction de la Recherche Clinique et de l'Innovation - Hôpitaux Universitaires de Strasbourg</organization>
  </responsible_party>
  <keyword>Busulfan</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>respiratory function assessment</keyword>
  <keyword>Busulfan pharmacokinetic and respiratory function tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

